A significant shift in Canadian drug policy has happened, as the regulators permit the availability of psilocybin mushrooms for therapeutic applications. Previously, these substances were heavily restricted, but a increasing body of evidence suggests they could offer benefits for psychological issues like depression. This development represents a s